# Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT01863550** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 1087 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT01863550
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-12-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2034-02-05
- **Target enrollment:** 1087 (ACTUAL)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863550, "Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01863550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*